30results about How to "Enough purity" patented technology

The invention relates to the technical field of medicine, and concretely relates to various different types substituted N-(5-(quinolyl-6-yl) pyridyl-3-yl)benzsulfamide derivatives represented by formula (1) (all groups in the formula (1) are defined in the specification. The above compounds have a good antitumor activity against a plurality of tumors comprising human lung cancer, colon cancer, liver cancer, breast cancer, cerebral astrocytoma and the like, lays a foundation for the development of antitumor medicines having the advantages of high efficiency, low toxicity and strong specificity, and has a very good exploitation value. The invention also relates to a composition containing the compounds, a preparation method of the composition, and a use of the composition in the preparation of the antitumor medicines.

The invention introduces a discontinuous crystallization unit for the production of ball- shaped crystals comprising a crystallizer (1) that consists of a metallic cylindrical vessel with its inner surface of a hard material, with an oval or circular cross-section with a conical or vaulted bottom (12), fitted along its length with a duplicator (4) for cooling of the solution and / or suspension of the solution and crystals and a high-speed agitator (8) of a hard material with a drive (9) enabling speed control and thus the rate of the impact of the mechanical action of the agitator on roundness of crystals inside the vessel together with the inner surface of the vessel containing at least 2 baffles (5) of a hard material while the vessel is fitted with at least 1 orifice (10) at the top that at least 1 independent branch of the circulation circuit (11) is connected to from the outside for the inlet of a heated solution and / or heated suspension of the solution and crystals by means of at least 1 circulation pump (2) and through at least 1 heat exchanger (3) and together with the duplicator (4) ensuring controlled periodic changes of temperatures of the crystal suspension around the cooling curve while an interconnection (13) pipeline is connected to the bottom (12) of the crystallizer (1) vessel that is connected to at least one branch of the circulation circuit (11).

The invention relates to a method for the producton of silicon organic compounds modified by a phosphonic acid ester by reacting at least one silane having formula [(R<3>O) fR<1>3-fSiCR<2>2P (O) (OR<4>) 2] (III) with at least one silicon compound having general formula (R2SiO2 / 2) p (R3SiO1 / 2) q [O1 / 2H] m (IV), wherein R<3> represents hydrogen or a C1-C20-hydrocarbon radical optionally substituted by -CN or a halogen atom, and m represents a whole number of 1 or 2, and R, R<1>, R<2>, R<3>, R<4>, m, p, q, f and s have the meaning cited in the description.

The invention discloses a water-treatment composite microbe continuous culture device and a culture method thereof. The device comprises a tank (1), the tank (1) is separated into four independent culture zones comprising an aerobic zone (3), an anaerobic zone (4), a first transition zone (5) and a second transition zone (6) by separation plates (2), the first transition zone (5) and the second transition zone (6) are positioned between the aerobic zone (3) and the anaerobic zone (4), each of the culture zones is provided with a culture medium inlet (7) and an overflow mouth (8), a culture medium is continuously charged through the culture medium inlet (7), and a cultured bacterial liquid flows to a sewage treatment zone from the overflow mouth (8). The device and the method have the advantages of realization of the simultaneous and continuous culture of a plurality of strains, automatic addition of the culture medium, automatic charging of the bacterial liquid, improvement of the culture efficiency of the bacterial liquid, substantial acceleration of the composite pollution treatment speed, and avoiding of the sewage-treatment intermittent interruption caused by intermittent culture.

The invention provides 20(S)-camptothecin ramification demonstrated by the figure (1) or its acceptable salt in the medicine. The m in the figure is one integer between 2 and 5; R is OH, OR1 (R1 is the alkyl of C1-5), NH2, NHR1 (R1 is the alkyl of C1-5) or NR1R2 ((R1 and R2 are the alkyl of C1-5 respectively). The invention also provides the preparation method of the ramification and its use in the antineoplastic medicines.

The invention relates to a discontinuous crystallization unit for the preparation of spherical crystals, comprising a crystallizer (1) consisting of a metal cylindrical container with a hard material inner surface, with an elliptical shaped or circular cross-section and tapered or arched bottom (12), along the length of said metal cylindrical vessel is mounted a replicator (4) for cooling the solution and / or suspension of solution and crystals; and hard A high-speed stirrer (8) for the material with a drive (9) that achieves speed control and is thus connected to the interior of the vessel with at least 2 hard material baffles (5) The surfaces together control the impact rate of the mechanical action of the stirrer on the crystal roundness in the container, and at the same time at least 1 orifice (10) is installed on the top of the container, and the branch of at least 1 independent circulation loop (11) is connected to the said at least 1 orifice (10) for feeding heated solution and / or heated solution and suspension of crystals via at least 1 circulation pump (2) and via at least 1 heat exchanger (3) , which together with the replicator (4) ensures a controlled periodic variation of the temperature of the crystal suspension around the cooling curve, while connecting the interconnection (13) pipeline to the crystallizer (1) vessel bottom (12), which connects At least one branch to the circulation loop (11).

A benzopyran compound or its salts, their preparing process and their application in preparing medicine for treating B-type diabetes are disclosed.

A lactamic acid compound or its salt, its two preparing processes, and its application in preparing medicine to treat diabetes B are disclosed.

The invention discloses a new application of thio-taxane derivatives which have the structure shown in formula (1), wherein R is hydrogen, C1-18 are alkyl groups, C1-18 are substituted alkyl groups, C2-10 are alkenyl groups, C2-10 are alkynyl, C3-6 are naphthenic base, C4-6 are cyclenes base, aryl, substituted aryl, heterocyclic groups or substituted heterocyclic groups, and the substituent is one or several types selected from C1-8 alkyl groups, C1-8 alkoxy, C1-8 halogenated alkyl, halogen, aryl, nitryl or amino. The thio-taxane derivative can be used for preparing medicines for treating hepatitis B.

This invention relates to the isolation of iodixanol (1,3-bis(acetamido)-N,N'-bis[3,5-bis(2,3-dihydroxypropylaminocarbonyl)-2,4,6-triiodophenyl]-2-hydroxypropane), more specifically to the isolation of iodixanol from an aqueous solution.

The invention belongs to the technical field of medicinal chemistry, and relates to a novel matrix metal protease inhibitor and medicinal use thereof. The inhibitor is benzamide ilomastat derivative as shown in a formula (1) defined in the description, wherein R1 includes but is not limited to 2-NH2, an amino group is substituted with an acetyl amino group, R2 includes but is not limited to aromatic groups such as hydrogen atoms, fluorine, chlorine, bromine, a methyl group, an ethyl group, NH2, substituted amino, a methoxyl group, an ethoxy group, a trifluoromethyl group, a cyclohexyl group, a phenyl group, substituted phenyl, thiophene, pyrrole, furan, thiazole and pyridine, and the substituted phenyl of R2 includes but is not limited to radical groups such as a methyl group, an ethyl group, a methoxyl group, an ethoxy group, a trifluoromethyl group, a hydroxyl group, fluorine, chlorine, bromine, an acetyl group and benzophenone connected with 4' position of a benzene ring. Experiments show that the benzamide ilomastat derivative can be used for preparing drugs for resisting invasion and diffusion of tumors such as a liver cancer, a lung cancer, a breast cancer and an ovarian cancer.

The invention relates to a synthesis method of a ruxolitinib intermediate. The method comprises the following steps: firstly, carrying out catalytic reaction on cyclopentane methyl formate and acetonitrile to prepare 3-cyclopentyl-3-oxypropionitrile; carrying out enzymatic asymmetric reduction on 3-cyclopentyl-3-oxypropionitrile to generate chiral alcohol (S)-3-cyclopentyl-3-oxypropionitrile; and carrying out Mitsunobu reaction and 4-bromopyrazole coupling on (S)-3-cyclopentyl-3-oxypropionitrile to obtain ruxolitinib intermediate (3R)-3-(4-bromo-1H-pyrazole-1-yl)-3-cyclopentane propionitrile. The synthesis method has the advantages of short route, low cost, mild condition and good stereoselectivity, and is suitable for industrialized mass production.

The invention provides a method for extracting tungsten from a tungsten-containing sodium carbonate solution and comprehensively utilizing an extracted solution. The method comprises the following steps of firstly, adsorbing tungsten in the tungsten-containing sodium carbonate solution by using ion exchange resin to obtain an exchanged solution and negative tungsten resin, and desorbing the negative tungsten resin under the closed condition of 40 to 60DEG C by using ammonia water; secondly, carrying out ball milling and size mixing on barium carbonate and part of exchanged solution; thirdly, slowly adding size obtained by ball milling into a stirring tank which is filled with residual exchanged solution and starts stirring, and stirring at the temperature of 60 to 90DEG C for 4 to 10 hours; fourthly, passivating barium sulfate: carrying out ball milling and size mixing on a filter cake obtained in the third step and a proper amount of water in a ball mill, then mixing with a sulfuric acid solution, stirring for 4 to 10 hours, then filtering, and washing the filter cake with deionized water to obtain a barium sulfate product. According to the method provided by the invention, the discharging amounts of waste water and waste salts in tungsten metallurgy are greatly reduced, and 50 percent or over 50 percent of sodium carbonate is recovered; meanwhile, the barium sulfate product with a higher added value is obtained, and significant comprehensive economic benefits are obtained.